Lipid-modifying drugs subclasses.

Background Cardiovascular disease (CVD) is the leading cause of mortality and morbidity in China and worldwide while we are lacking in validated primary prevention model specifically for Chinese. To identify CVD high-risk individuals for early intervention, we created and validated a primary prevention risk prediction model, Personalized CARdiovascular DIsease risk Assessment for Chinese (1°P-CARDIAC), in contemporary Chinese cohorts in Hong Kong. Methods Patients without any history of CVD was categorized as derivation and validation cohorts based on their different geographical location of residence in Hong Kong. The outcome was the first diagnosis of a composite of coronary heart disease, ischemic or hemorrhagic stroke, peripheral artery disease, and revascularization. The full model incorporated all available variables in the dataset as clinical laboratory tests, disease and medication history, family history of disease, demographic factors, and healthcare utilization. We employed XGBoost Cox model and multivariate imputation with chained equation (MICE) for derivation and missing data replacement. A basic model was developed with the integration of statistically significant and important subset of risk variables by least absolute shrinkage and selection operator (LASSO) regression. Validation was performed by 1000 bootstrap replicates and compared to four existing models: PREDICT, pooled cohort equation (PCE), China-PAR, and Framingham (Asian). Results The study included 179,953 patients in the derivation cohort and 1,083,924 patients across two independent validation cohorts. A total of 103 covariates were included in the full model whilst 8 covariates were included the basic model. It demonstrated good performance with C-statistic of 0.87 (95% CI: 0.87, 0.87), calibration slope of 0.94 in the full model. The C-statistic in the basic model was 0.75 (95% CI: 0.75, 0.75) with calibration slope of 0.91. Other comparison risk models have lower C statistic ranging from 0.68 to 0.72. Conclusion We developed and ...